Edwards Lifesciences (EW) Short-term Investments (2011 - 2026)

Edwards Lifesciences' Short-term Investments history runs 16 years deep, the most recent figure standing at $1.2 billion for Q1 2026.

• On a quarterly basis, Short-term Investments rose 61.76% year-over-year to $1.2 billion in Q1 2026; TTM through Mar 2026 was $1.2 billion, a 61.76% increase from a year earlier, with the FY2025 full-year figure at $1.3 billion, up 38.42% from the prior year.
• Short-term Investments declined to $1.2 billion in Q1 2026 per EW's latest filing, from $1.3 billion in the prior quarter.
• Across five years, Short-term Investments topped out at $1.3 billion in Q4 2025 and bottomed at $317.7 million in Q2 2022.
• The 5-year median for Short-term Investments is $490.9 million (2022), against an average of $662.3 million.
• Biggest YoY gain for Short-term Investments was 197.31% in 2022; the steepest drop was 26.11% in 2022.
• Year by year, Short-term Investments stood at $446.3 million in 2022, then gained by 12.14% to $500.5 million in 2023, then surged by 85.95% to $930.7 million in 2024, then jumped by 38.42% to $1.3 billion in 2025, then slipped by 4.84% to $1.2 billion in 2026.
• Per Business Quant, the three latest EW Short-term Investments figures stand at $1.2 billion (Q1 2026), $1.3 billion (Q4 2025), and $1.2 billion (Q3 2025).